Nasdaq
$99.80▼ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.50BShares out 65.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 3d agoPre-market26.10.22 20:308-KKey event#●●●#●●●
Lantheus Holdings, Inc.
Lantheus Holdings received a 'Second Request' for additional information and documentary materials from the FTC regarding its pending merger with Curium US Holdings. This action extends the waiting period under the HSR Act, though the companies continue to expect the merger to close in the first half of 2027.…more
$99.80-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 05:308-KKey event
Lantheus Holdings, Inc.
Lantheus Holdings approved the merger agreement with Curium US Holdings LLC at a special meeting of stockholders held on October 14, 2026. The merger proposal was passed with 55,457,863 votes in favor, and Lantheus will become a wholly owned subsidiary of Curium upon completion of the transaction.…more
$99.80-0.01%vs prev closeView filingShare - 10.2After-hours26.10.03 06:02DEFA14AOther
Lantheus Holdings, Inc.
Lantheus Holdings has issued supplemental disclosures in response to shareholder lawsuits and demands regarding its merger with Curium. The company reaffirms the validity of the merger agreement and provides additional details on Morgan Stanley's financial analysis and potential conflicts of interest ahead of the special meeting of stockholders scheduled for October 14, 2026.…more
$99.80-0.01%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:34#●●●#●●●
Lantheus-Curium Merger Delayed by FTC Second Request
The merger between Lantheus and Curium has been extended following a second request for information from the FTC. Both companies intend to respond promptly to comply with regulatory requirements.…more
$99.80-0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Pre-market26.09.30 21:30
●●●●●●●● ●●●●● ●●●●●●
Lantheus announced that its new prostate cancer imaging agent, PYLARIFY TruVu, has been granted Transitional Pass-Through payment status and a permanent HCPCS code by the CMS. This designation is expected to facilitate patient access and simplify reimbursement processes in hospital outpatient settings.…more
$99.80-0.01%vs prev close - 9.28Pre-market26.09.28 21:00
●●●●●●●● ●●●●● ●●●●●●
Lantheus has dosed the first patient in its Phase 2/3 SPARROW trial evaluating the investigational prostate cancer imaging agent LNTH-2401. The study aims to assess the diagnostic performance and safety of the candidate, marking a key milestone in the company's radiopharmaceutical pipeline.…more
$99.80-0.01%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report